Biogen (NASDAQ:BIIB) Price Target Raised to $275.00 at Oppenheimer

Biogen (NASDAQ:BIIB) had its target price increased by equities researchers at Oppenheimer from $250.00 to $275.00 in a research report issued to clients and investors on Wednesday,MarketScreener reports. The firm currently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price target would suggest a potential upside of 49.80% from the stock’s current price.

BIIB has been the subject of several other research reports. Piper Sandler boosted their price objective on shares of Biogen from $157.00 to $177.00 and gave the company a “neutral” rating in a research note on Monday, February 9th. Weiss Ratings restated a “hold (c-)” rating on shares of Biogen in a research report on Monday, December 29th. Guggenheim increased their price objective on Biogen from $185.00 to $246.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. Truist Financial lifted their price objective on Biogen from $190.00 to $193.00 and gave the company a “hold” rating in a research note on Monday, February 9th. Finally, Tudor Pickering set a $201.00 target price on Biogen in a research report on Monday, February 9th. Twelve equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $207.96.

Biogen Stock Performance

Shares of BIIB opened at $183.58 on Wednesday. The stock’s 50-day simple moving average is $186.19 and its 200 day simple moving average is $170.98. The stock has a market capitalization of $26.94 billion, a price-to-earnings ratio of 20.67, a price-to-earnings-growth ratio of 1.49 and a beta of 0.15. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.03 and a current ratio of 2.68. Biogen has a 52-week low of $110.04 and a 52-week high of $202.41.

Biogen (NASDAQ:BIIB) last posted its earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a return on equity of 12.64% and a net margin of 13.07%.The business had revenue of $2.28 billion during the quarter, compared to analyst estimates of $2.21 billion. During the same quarter in the previous year, the firm earned $3.44 EPS. The company’s quarterly revenue was down 7.2% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Research analysts forecast that Biogen will post 15.83 EPS for the current fiscal year.

Insiders Place Their Bets

In other Biogen news, insider Priya Singhal sold 2,660 shares of the firm’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider owned 8,043 shares in the company, valued at $1,607,232.69. This trade represents a 24.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. 0.18% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Biogen

Several institutional investors have recently bought and sold shares of the business. Norges Bank bought a new position in shares of Biogen in the 4th quarter valued at about $464,408,000. Boston Partners purchased a new position in shares of Biogen in the 4th quarter worth approximately $302,815,000. Fred Alger Management LLC increased its position in shares of Biogen by 39,074.8% during the 4th quarter. Fred Alger Management LLC now owns 798,774 shares of the biotechnology company’s stock valued at $140,576,000 after purchasing an additional 796,735 shares during the last quarter. Employees Provident Fund Board bought a new stake in shares of Biogen in the 4th quarter worth about $123,931,000. Finally, Orion Porfolio Solutions LLC lifted its stake in shares of Biogen by 6,828.4% during the 2nd quarter. Orion Porfolio Solutions LLC now owns 517,275 shares of the biotechnology company’s stock worth $64,965,000 after acquiring an additional 509,809 shares during the last quarter. Institutional investors own 87.93% of the company’s stock.

Key Headlines Impacting Biogen

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Canaccord raised its price target on BIIB to $245 and reiterated a Buy rating, implying meaningful upside versus current levels — a bullish analyst signal that can support share gains. Canaccord raises BIIB PT to $245Article
• Positive Sentiment: FDA approved a higher‑dose SPINRAZA regimen, strengthening Biogen’s rare‑disease franchise and supporting longer‑term revenue potential from SMA treatments. FDA clears higher‑dose SPINRAZAArticle
• Neutral Sentiment: Biogen agreed to acquire Apellis for ~$5.6B in cash (plus potential contingent payments), adding commercial immunology and nephrology assets (SYFOVRE, EMPAVELI) that bolster growth strategy but require execution and integration. Biogen to buy Apellis for $5.6BArticle
• Neutral Sentiment: Market reaction: Apellis stock surged (big premium to APLS holders), validating the bid price, but the takeover effectively caps Apellis upside — an outcome analysts note while weighing Biogen’s strategic gain versus cash outlay. Apellis hits 2‑year high after Biogen dealArticle
• Negative Sentiment: A law firm launched an investor probe into the proposed Apellis sale, creating potential legal/transactional friction and additional uncertainty around deal process or pricing. Investor alert — probe into Apellis saleArticle
• Negative Sentiment: Several analysts remain cautious on Biogen (and some on Apellis), keeping Hold/neutral ratings and warning the deal may cap upside or not materially change near‑term catalysts — this analyst skepticism can weigh on BIIB near term. Analysts remain cautious despite positivesArticle

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.